Merck KGaA agreed to acquire Bio-Techne for approximately $11.3 billion, expanding the German company’s life science tools footprint across multiomics, spatial biology, cell and gene therapy, and analytical workflows. The deal values Bio-Techne at $73 per share in cash, representing a 36% premium to its one-month volume-weighted average price. Bio-Techne brings ProteinSimple systems such as automated protein analysis and RNAscope multiplex in situ hybridization capabilities, alongside recombinant proteins, antibodies, and immunoassays. The transaction also includes cell culture device maker Wilson Wolf, which Bio-Techne is acquiring, with Merck expecting synergies of roughly €140 million by year three after closing. Merck said it plans to fund the acquisition through a combination of existing cash and new debt, targeting deal close by late 2026 or early 2027. The strategic logic is to offer customers more end-to-end coverage from discovery and translational research through development, testing, and manufacturing.